Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Int J Dev Biol. 2015 Jan 1;59(7-9):313–325. doi: 10.1387/ijdb.150206am

Fig. 3. Expression of TPC2 in the SMCs of intact embryos.

Fig. 3

Embryos were fixed between 16 hpf and 24 hpf and then dual immunolabelled with a (Ai-Ii) myosin heavy chain and (Aii–Iii) TPC2 antibody. (F-I) Some embryos were injected with (F) standard control-MO, (G) p53-MO, (H) TPCN2-MO + p53-MO or (I) TPCN2-MO + p53-MO + TPCN2-mRNA between the 1-4-cell stage and then fixed at 24 hpf prior to immunolabeling. (Aiii–Iiii) Line-scan analyses were performed along individual myofibers and (Aiv-Iiv) graphs were plotted to show the development of TPC2 expression over time. The regions bounded by the blue rectangles in panels Ei and Eii are shown at higher magnification in panels Ji and Jii. (Jiii) The myosin heavy chain and TPC2 images when merged. (Jiv) Line-scan analysis showing the localization of TPC2 in relation to that of the myosin heavy chain in more detail. (K) Schematic representation of two sarcomeres. (Li) End view of several myofibers showing the localization of TPC2 in relation to the myosin heavy chain. (Lii) Schematic transverse section through an embryo at 24 hpf showing the location of TPC2 in relation to the SMCs and other cell types (modified from Fig. 1B in Du et al., 1997). Scale bars, 10 μm (A-I); 5 μm (J, L).